Novel CAR-T Regulatory Cell Therapy Shows Promise in Refractory Rheumatoid Arthritis
核心洞察
SBT777101, an autologous CAR-T regulatory cell therapy targeting citrullinated proteins (搜索), demonstrated a promising safety profile in the first-in-human Regulate-RA phase 1 trial for highly refractory rheumatoid arthritis (搜索) patients.
The therapy showed no dose-limiting toxicities, cytokine release syndrome, or immune cell-associated neurotoxicity syndrome through the first two dose levels in the 3+3 dose escalation study design.
Preliminary data revealed promising mechanistic and clinical evidence of therapeutic activity, with most adverse events being mild to moderate in severity and self-limited.
A novel chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy has demonstrated encouraging safety results and preliminary efficacy signals in patients with highly refractory rheumatoid arthritis (搜索), according to phase 1 data presented at ACR Convergence 2025.
The investigational therapy, SBT777101, represents an autologous regulatory T-cell product engineered with a CAR specific for citrullinated proteins (搜索)—a key target in rheumatoid arthritis (搜索) pathogenesis. The Regulate-RA trial marks the first-in-human study of engineered Treg cells in this patient population.
Safety Profile Exceeds Expectations
"The safety summary for SBT777101 has been well-tolerated at dose levels 1 and 2," said Minna Kohler, MD, RhMSUS, founder and director of the Rheumatology Musculoskeletal Ultrasound Program at Massachusetts General Hospital and study investigator. "The primary endpoint was safety and tolerability, and thus far, through the first two dose levels, there were no DLTs, no CRS and no ICANS."
The absence of dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), and immune cell-associated neurotoxicity syndrome (ICANS) represents a significant safety milestone for this novel cellular therapy approach. Most adverse events observed were mild to moderate in severity and self-limited.
Study Design and Patient Population
Participants in the Regulate-RA trial were enrolled using a 3+3 dose escalation study design, with preliminary results presented for cohorts 1 and 2. The study specifically targets patients with highly refractory rheumatoid arthritis (搜索)—a population with limited therapeutic options despite the availability of multiple disease-modifying antirheumatic drugs and biologics.
Kohler noted that enrollment of cohort 3 is ongoing, indicating continued advancement of the dose escalation phase.
Mechanistic Innovation
The therapy's targeting of citrullinated proteins (搜索) represents a mechanistically novel approach to rheumatoid arthritis (搜索) treatment. Citrullination is a post-translational modification process that plays a central role in the autoimmune response characteristic of rheumatoid arthritis, making it an attractive therapeutic target.
By engineering regulatory T cells with CARs specific for these citrullinated proteins (搜索), SBT777101 aims to restore immune tolerance and reduce the inflammatory response driving joint destruction in rheumatoid arthritis (搜索).
Early Efficacy Signals
Beyond the favorable safety profile, Kohler shared that preliminary data showed "promising mechanistic and clinical evidence of efficacy." While detailed efficacy data were not fully disclosed in the preliminary presentation, the early signals suggest the therapy may provide meaningful clinical benefit for this challenging patient population.
The development of SBT777101 adds to a growing pipeline of cellular therapies being investigated for autoimmune diseases, representing a potential paradigm shift from traditional immunosuppressive approaches to more targeted immune modulation strategies.